Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected ETFs tracking the performance of weight-loss drugs have largely underperformed since launching in late 2023
Wium-Andersen IK, Osler M, Jorgensen MB, Rungby J, Wium-Andersen MK
The benefits and risks of using these medicines for weight loss in people who arent obese or overweight with health problems havent been studied
Mochi Health GLP-1 medications for weight loss review
Please note that deals can expire, and all prices are subject to change
Patients should inform their healthcare providers about any kidney disease, significant weight changes, or other medications they are taking, as these factors may influence both the therapeutic effects and elimination timeline of GLP-1 receptor agonists